Skip to main content

Advertisement

SpringerLink
Log in

Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Heart failure and atrial fibrillation are common and responsible for significant mortality of patients. Both share the same risk factors like hypertension, ischemic heart disease, diabetes, obesity, arteriosclerosis, and age. A variety of microscopic and macroscopic changes favor the genesis of atrial fibrillation in patients with preexisting heart failure, altered subcellular Ca2+ homeostasis leading to increased cellular automaticity as well as concomitant fibrosis that are induced by pressure/volume overload and altered neurohumoral states. Atrial fibrillation itself promotes clinical deterioration of patients with preexisting heart failure as atrial contraction significantly contributes to ventricular filling. In addition, atrial fibrillation induced tachycardia can even further compromise ventricular function by inducing tachycardiomyopathy. Even though evidence has been provided that atrial functions significantly and independently of confounding ventricular pathologies, correlate with mortality of heart failure patients, rate and rhythm controls have been shown to be of equal effectiveness in improving mortality. Yet, it also has been shown that cohorts of patients with heart failure benefit from a rhythm control concept regarding symptom control and hospitalization. To date, amiodarone is the most feasible approach to restore sinus rhythm, yet its use is limited by its extensive side-effect profile. In addition, other therapies like catheter-based pulmonary vein isolation are of increasing importance. A wide range of heart failure-specific therapies are available with mixed impact on new onset or perpetuation of atrial fibrillation. This review highlights pathophysiological concepts and possible therapeutic approaches to treat patients with heart failure at risk for or with atrial fibrillation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Dawber TR, Meadors GF, Moore FE Jr (1951) Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health 41:279–281

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Lubitz SA, Moser C, Sullivan L, Rienstra M, Fontes JD, Villalon ML, Pai M, McManus DD, Schnabel RB, Magnani JW, Yin X, Levy D, Pencina MJ, Larson MG, Ellinor PT, Benjamin EJ (2013) Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc 2:e000126

    Article  PubMed  PubMed Central  Google Scholar 

  3. Maisel WH, Stevenson LW (2003) Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 91:2D–8D

    Article  PubMed  Google Scholar 

  4. Nicod P, Hillis LD, Winniford MD, Firth BG (1986) Importance of the “atrial kick” in determining the effective mitral valve orifice area in mitral stenosis. Am J Cardiol 57:403–407

    Article  CAS  PubMed  Google Scholar 

  5. Rahimtoola SH, Ehsani A, Sinno MZ, Loeb HS, Rosen KM, Gunnar RM (1975) Left atrial transport function in myocardial infarction. Importance of its booster pump function. Am J Med 59:686–694

    Article  CAS  PubMed  Google Scholar 

  6. Bonow RO, Frederick TM, Bacharach SL, Green MV, Goose PW, Maron BJ, Rosing DR (1983) Atrial systole and left ventricular filling in hypertrophic cardiomyopathy: effect of verapamil. Am J Cardiol 51:1386–1391

    Article  CAS  PubMed  Google Scholar 

  7. Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415:219–226

    Article  CAS  PubMed  Google Scholar 

  8. Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XH, Nattel S, Dobrev D (2014) Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. Circulation 129:145–156

    Article  CAS  PubMed  Google Scholar 

  9. Verheule S, Sato T, Everett T, Engle SK, Otten D, Rubart-von der Lohe M, Nakajima HO, Nakajima H, Field LJ, Olgin JE (2004) Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 94:1458–1465

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S (2001) Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608–2614

    Article  CAS  PubMed  Google Scholar 

  11. Mary-Rabine L, Albert A, Pham TD, Hordof A, Fenoglio JJ Jr, Malm JR, Rosen MR (1983) The relationship of human atrial cellular electrophysiology to clinical function and ultrastructure. Circ Res 52:188–199

    Article  CAS  PubMed  Google Scholar 

  12. Ouadid H, Albat B, Nargeot J (1995) Calcium currents in diseased human cardiac cells. J Cardiovasc Pharmacol 25:282–291

    Article  CAS  PubMed  Google Scholar 

  13. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A, Nattel S (2000) Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 101:2631–2638

    Article  CAS  PubMed  Google Scholar 

  14. Diness JG, Bentzen BH, Sorensen US, Grunnet M (2015) Role of calcium-activated potassium channels in atrial fibrillation pathophysiology and therapy. J Cardiovasc Pharmacol 66:441–448

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dibb KM, Clarke JD, Eisner DA, Richards MA, Trafford AW (2013) A functional role for transverse (t-) tubules in the atria. J Mol Cell Cardiol 58:84–91

    Article  CAS  PubMed  Google Scholar 

  16. Wehrens XH, Lehnart SE, Reiken SR, Marks AR (2004) Ca2+/calmodulin-dependent protein kinase II phosphorylation regulates the cardiac ryanodine receptor. Circ Res 94:e61–e70

    Article  CAS  PubMed  Google Scholar 

  17. Barlucchi L, Leri A, Dostal DE, Fiordaliso F, Tada H, Hintze TH, Kajstura J, Nadal-Ginard B, Anversa P (2001) Canine ventricular myocytes possess a renin-angiotensin system that is upregulated with heart failure. Circ Res 88:298–304

    Article  CAS  PubMed  Google Scholar 

  18. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR (1972) Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286:441–449

    Article  CAS  PubMed  Google Scholar 

  19. Chelu MG, Sarma S, Sood S, Wang S, van Oort RJ, Skapura DG, Li N, Santonastasi M, Muller FU, Schmitz W, Schotten U, Anderson ME, Valderrabano M, Dobrev D, Wehrens XH (2009) Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest 119:1940–1951

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Schmidt C, Wiedmann F, Zhou XB, Heijman J, Voigt N, Ratte A, Lang S, Kallenberger SM, Campana C, Weymann A, De Simone R, Szabo G, Ruhparwar A, Kallenbach K, Karck M, Ehrlich JR, Baczko I, Borggrefe M, Ravens U, Dobrev D, Katus HA, Thomas D (2017) Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy. Eur Heart J 38:1764–1774

    PubMed  Google Scholar 

  21. Hohendanner F, McCulloch AD, Blatter LA, and Michailova AP. Calcium and IP3 dynamics in cardiac myocytes: experimental and computational perspectives and approaches. Frontiers in Pharmacology 5: 2014

  22. Hohendanner F, Walther S, Maxwell JT, Kettlewell S, Awad S, Smith GL, Lonchyna VA, Blatter LA (2015) Inositol-1,4,5-trisphosphate induced Ca2+ release and excitation-contraction coupling in atrial myocytes from normal and failing hearts. J Physiol 593:1459–1477

    Article  CAS  PubMed  Google Scholar 

  23. Greiser M, Kerfant BG, Williams GS, Voigt N, Harks E, Dibb KM, Giese A, Meszaros J, Verheule S, Ravens U, Allessie MA, Gammie JS, van der Velden J, Lederer WJ, Dobrev D, Schotten U (2014) Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. J Clin Invest 124:4759–4772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, Chugh SS, Corradi D, D’Avila A, Dobrev D, Fenelon G, Gonzalez M, Hatem SN, Helm R, Hindricks G, Ho SY, Hoit B, Jalife J, Kim YH, Lip GY, Ma CS, Marcus GM, Murray K, Nogami A, Sanders P, Uribe W, Van Wagoner D, Nattel S, Document R, Centurion OA, Kuck KH, Patton KK, Sapp JL, Stiles M, Svendsen JH, Upadhyay GA, Review C, and Shantsila A. EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: definition, characterization, and clinical implication. Europace 2016

  25. Gronefeld GC, Hohnloser SH (2003) Heart failure complicated by atrial fibrillation: mechanistic, prognostic, and therapeutic implications. J Cardiovasc Pharmacol Ther 8:107–113

    Article  PubMed  Google Scholar 

  26. Schotten U, Verheule S, Kirchhof P, Goette A (2011) Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 91:265–325

    Article  PubMed  Google Scholar 

  27. Latchamsetty R, Morady F (2011) Complex fractionated atrial electrograms: a worthwhile target for ablation of atrial fibrillation? Circ Arrhythm Electrophysiol 4:117–118

    Article  PubMed  Google Scholar 

  28. Santos AB, Roca GQ, Claggett B, Sweitzer NK, Shah SJ, Anand IS, Fang JC, Zile MR, Pitt B, Solomon SD, Shah AM (2016) Prognostic relevance of left atrial dysfunction in heart failure with preserved ejection fraction. Circ Heart Fail 9:e002763

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ben Morrison T, Jared Bunch T, Gersh BJ (2009) Pathophysiology of concomitant atrial fibrillation and heart failure: implications for management. Nat Clin Pract Cardiovasc Med 6:46–56

    Article  CAS  PubMed  Google Scholar 

  30. Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L, Catanzariti D, Molon G, Botto GL, La Rocca L, Grammatico A, Boriani G, cardiological centers participating in ClinicalService P (2011) Device-detected atrial tachyarrhythmias predict adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol 57:167–172

    Article  PubMed  Google Scholar 

  31. Whellan DJ, Ousdigian KT, Al-Khatib SM, Pu W, Sarkar S, Porter CB, Pavri BB, O’Connor CM, Investigators PS (2010) Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (program to access and review trending information and evaluate correlation to symptoms in patients with heart failure) study. J Am Coll Cardiol 55:1803–1810

    Article  PubMed  Google Scholar 

  32. Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Della Bella P, Nakai T, Reisman M, DiMario C, Block P, Kramer P, Fleschenberg D, Krumsdorf U, Scherer D (2002) Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 105:1887–1889

    Article  PubMed  Google Scholar 

  33. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P, Investigators PA (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374:534–542

    Article  CAS  PubMed  Google Scholar 

  34. Gloekler S, Saw J, Koskinas KC, Kleinecke C, Jung W, Nietlispach F, Meier B (2017) Left atrial appendage closure for prevention of death, stroke, and bleeding in patients with nonvalvular atrial fibrillation. Int J Cardiol

  35. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD, Atrial fibrillation follow-up investigation of rhythm management I (2002) A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347:1825–1833

    Article  CAS  PubMed  Google Scholar 

  36. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg MP, Investigators RI (2010) Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med 362:1363–1373

    Article  PubMed  Google Scholar 

  37. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 18:1609–1678

    Article  PubMed  Google Scholar 

  38. Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, Svendsen JH, Vos MA, Anker SD, Coats AJ, Haverkamp W, Manolis AS, Chung MK, Sanders P, Pieske B (2015) European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail 17:848–874

    Article  PubMed  Google Scholar 

  39. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group N Engl J Med 341:857–865

    CAS  Google Scholar 

  40. Abraham JM, Saliba WI, Vekstein C, Lawrence D, Bhargava M, Bassiouny M, Janiszewski D, Lindsay B, Militello M, Nissen SE, Poe S, Tanaka-Esposito C, Wolski K, Wilkoff BL (2015) Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 8:772–776

    Article  CAS  PubMed  Google Scholar 

  41. Hoit BD (2014) Left atrial size and function: role in prognosis. J Am Coll Cardiol 63:493–505

    Article  PubMed  Google Scholar 

  42. Ionescu-Ittu R, Abrahamowicz M, Jackevicius CA, Essebag V, Eisenberg MJ, Wynant W, Richard H, Pilote L (2012) Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med 172:997–1004

    Article  PubMed  Google Scholar 

  43. Naccarelli GV, Wolbrette DL, Khan M, Bhatta L, Hynes J, Samii S, Luck J (2003) Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Am J Cardiol 91:15D–26D

    Article  CAS  PubMed  Google Scholar 

  44. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN (1998) Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 98:2574–2579

    Article  CAS  PubMed  Google Scholar 

  45. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL, Atrial F, Congestive Heart Failure I (2008) Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667–2677

    Article  CAS  PubMed  Google Scholar 

  46. Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider K (2013) Improving outcomes in patients with atrial fibrillation: rationale and design of the early treatment of atrial fibrillation for stroke prevention trial. Am Heart J 166:442–448

    Article  PubMed  Google Scholar 

  47. Rudo T, Kowey P (2006) Atrial fibrillation: choosing an antiarrhythmic drug. Curr Cardiol Rep 8:370–376

    Article  PubMed  Google Scholar 

  48. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K (2003) Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 41:2197–2204

    Article  CAS  PubMed  Google Scholar 

  49. Hanna IR, Heeke B, Bush H, Brosius L, King-Hageman D, Dudley SC Jr, Beshai JF, Langberg JJ (2006) Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3:881–886

    Article  PubMed  PubMed Central  Google Scholar 

  50. Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S (2003) Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92:1379–1383

    Article  CAS  PubMed  Google Scholar 

  51. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Alexandru Popescu B, Schotten U, Van Putte B, Vardas P (2017) 2016 ESC guidelines for the Management of Atrial Fibrillation Developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed) 70:50

    Google Scholar 

  52. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B (2016) Perioperative rosuvastatin in cardiac surgery. N Engl J Med 374:1744–1753

    Article  CAS  PubMed  Google Scholar 

  53. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN, Val-He FTI (2005) Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 149:548–557

    Article  CAS  PubMed  Google Scholar 

  54. McCullough PA, Cowan S (2012) Mineralocorticoid receptor antagonists and mortality in heart failure with concurrent atrial fibrillation. Circ Heart Fail 5:550–551

    Article  PubMed  Google Scholar 

  55. O'Meara E, Khairy P, Blanchet MC, de Denus S, Pedersen OD, Levesque S, Talajic M, Ducharme A, White M, Racine N, Rouleau JL, Tardif JC, Roy D, investigators A-C (2012) Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail 5:586–593

    Article  PubMed  Google Scholar 

  56. Faris R, Flather MD, Purcell H, Poole-Wilson PA, and Coats AJ. Diuretics for heart failure. Cochrane Database Syst Rev CD003838, 2006

  57. Gottdiener JS, Reda DJ, Williams DW, Materson BJ, Cushman W, Anderson RJ (1998) Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 98:140–148

    Article  CAS  PubMed  Google Scholar 

  58. Anne W, Willems R, Van der Merwe N, Van de Werf F, Ector H, Heidbuchel H (2004) Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. Heart 90:1025–1030

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M, and Document R. (2016) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC. Eur J Heart Fail 18:891–975

  60. Kotecha D, Flather MD, Altman DG, Holmes J, Rosano G, Wikstrand J, Packer M, Coats AJS, Manzano L, Bohm M, van Veldhuisen DJ, Andersson B, Wedel H, von Lueder TG, Rigby AS, Hjalmarson A, Kjekshus J, JGF C, Beta-blockers in heart failure collaborative G (2017) Heart Rate and Rhythm and the Benefit of Beta-Blockers in Patients With Heart Failure. J Am Coll Cardiol 69:2885–2896

    Article  CAS  PubMed  Google Scholar 

  61. Ahmed A, Rich MW, Love TE, Lloyd-Jones DM, Aban IB, Colucci WS, Adams KF, Gheorghiade M (2006) Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 27:178–186

    Article  CAS  PubMed  Google Scholar 

  62. Hauptman PJ, McCann P, Romero JM, Mayo M (2013) Reference laboratory values for digoxin following publication of Digitalis Investigation Group (DIG) trial data. JAMA Intern Med 173:1552–1554

    Article  CAS  PubMed  Google Scholar 

  63. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, Yusuf S, Pfeffer MA (2006) Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program. J Am Coll Cardiol 47:1997–2004

    Article  PubMed  Google Scholar 

  64. Fonarow GC, Abraham WT, Albert NM, Gattis WA, Gheorghiade M, Greenberg B, O’Connor CM, Yancy CW, Young J (2004) Organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF): rationale and design. Am Heart J 148:43–51

    Article  PubMed  Google Scholar 

  65. Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J (2014) Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ Heart Fail 7:1042–1049

    Article  PubMed  Google Scholar 

  66. Zakeri R, Chamberlain AM, Roger VL, Redfield MM (2013) Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 128:1085–1093

    Article  PubMed  PubMed Central  Google Scholar 

  67. Woods CE, Olgin J (2014) Atrial fibrillation therapy now and in the future: drugs, biologicals, and ablation. Circ Res 114:1532–1546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Sorenson LM, Vulich CM, McErlean ES, McCarthy PM (1992) The Maze procedure: a new treatment for atrial fibrillation. AACN Clin Issues Crit Care Nurs 3:209–219

    Article  CAS  PubMed  Google Scholar 

  69. Schaff HV, Dearani JA, Daly RC, Orszulak TA, Danielson GK (2000) Cox-Maze procedure for atrial fibrillation: Mayo Clinic experience. Semin Thorac Cardiovasc Surg 12:30–37

    Article  CAS  PubMed  Google Scholar 

  70. Hsu LF, Jais P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquie JL, Scavee C, Bordachar P, Clementy J, Haissaguerre M (2004) Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 351:2373–2383

    Article  CAS  PubMed  Google Scholar 

  71. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci ML, Schweikert R, Neuzil P, Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, Haissaguerre M, Natale A (2016) Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 133:1637–1644

    Article  PubMed  Google Scholar 

  72. Gentlesk PJ, Sauer WH, Gerstenfeld EP, Lin D, Dixit S, Zado E, Callans D, Marchlinski FE (2007) Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 18:9–14

    Article  PubMed  Google Scholar 

  73. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney V, Duncan E, Page SP, Ullah W, Unsworth B, Mayet J, Dhinoja M, Earley MJ, Sporton S, Schilling RJ (2014) A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 7:31–38

    Article  CAS  PubMed  Google Scholar 

  74. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, McDonagh TA, Underwood SR, Markides V, Wong T (2013) A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 61:1894–1903

    Article  PubMed  Google Scholar 

  75. Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba W, Wang P, Al-Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla V, Bonso A, Casella M, Raviele A, Haissaguerre M, Natale A, Investigators P-C (2008) Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 359:1778–1785

    Article  CAS  PubMed  Google Scholar 

  76. Al Halabi S, Qintar M, Hussein A, Alraies MC, Jones DG, Wong T, MacDonald MR, Petrie MC, Cantillon D, Tarakji KG, Kanj M, Bhargava M, Varma N, Baranowski B, Wilkoff BL, Wazni O, Callahan T, Saliba W, Chung MK (2015) Catheter ablation for atrial fibrillation in heart failure patients: a meta-analysis of randomized controlled trials. Jacc Clin Electrophysiol 1:200–209

    Article  PubMed  PubMed Central  Google Scholar 

  77. Moreno J, Zamorano JL (2014) The CABANA trial. Eur Heart J 35:1908–1909

    PubMed  Google Scholar 

  78. Marrouche NF, Brachmann J, Committee C-AS (2009) Catheter ablation versus standard conventional treatment in patients with left ventricular dysfunction and atrial fibrillation (CASTLE-AF)-study design. Pacing Clin Electrophysiol 32:987–994

    Article  PubMed  Google Scholar 

  79. Gasparini M, Auricchio A, Regoli F, Fantoni C, Kawabata M, Galimberti P, Pini D, Ceriotti C, Gronda E, Klersy C, Fratini S, Klein HH (2006) Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J Am Coll Cardiol 48:734–743

    Article  PubMed  Google Scholar 

  80. Leon AR, Greenberg JM, Kanuru N, Baker CM, Mera FV, Smith AL, Langberg JJ, DeLurgio DB (2002) Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation: effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 39:1258–1263

    Article  PubMed  Google Scholar 

  81. Alexander B, Sadiq F, Azimi K, Glover B, Antiperovitch P, Hopman WM, Jaff Z, Baranchuk A (2017) Reverse atrial electrical remodeling induced by cardiac resynchronization therapy. J Electrocardiol 50:610–614

    Article  PubMed  Google Scholar 

  82. Pellicori P, Zhang J, Lukaschuk E, Joseph AC, Bourantas CV, Loh H, Bragadeesh T, Clark AL, Cleland JG (2015) Left atrial function measured by cardiac magnetic resonance imaging in patients with heart failure: clinical associations and prognostic value. Eur Heart J 36:733–742

    Article  CAS  PubMed  Google Scholar 

Download references

Disclaimer

We attest that the article is the authors’ original work, has not received prior publication, and is not under consideration for publication elsewhere.

Author information

Authors and Affiliations

  1. Department of Cardiology, Charité University Medicine, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany

    Felix Hohendanner, F. R. Heinzel, F. Blaschke, B. M. Pieske, W. Haverkamp, H. L. Boldt & A. S. Parwani

  2. Partner Site Berlin, German Center for Cardiovascular Research (DZHK), Berlin, Germany

    Felix Hohendanner, F. R. Heinzel, F. Blaschke, B. M. Pieske, W. Haverkamp, H. L. Boldt & A. S. Parwani

  3. Department of Internal Medicine and Cardiology, German Heart Center, 13353, Berlin, Germany

    B. M. Pieske

Authors
  1. Felix Hohendanner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. R. Heinzel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. Blaschke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. M. Pieske
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Haverkamp
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H. L. Boldt
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. S. Parwani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felix Hohendanner.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hohendanner, F., Heinzel, F.R., Blaschke, F. et al. Pathophysiological and therapeutic implications in patients with atrial fibrillation and heart failure. Heart Fail Rev 23, 27–36 (2018). https://doi.org/10.1007/s10741-017-9657-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-017-9657-9

Keywords

Search

Navigation